Introduction: In Selective Internal Radiation Therapy (SIRT), Y is administered to primary/secondary hepatic lesions. An accurate pre-treatment planning using Tc-MAA SPECT/CT allows the assessment of its feasibility and of the activity to be injected. Unfortunately, SPECT/CT suffers from patient-specific respiratory motion which causes artifacts and absorbed dose inaccuracies. In this study, a data-driven solution was developed to correct the respiratory motion.

Methods: The tool realigns the barycenter of SPECT projection images and shifts them to obtain a fine registration with the attenuation map. The tool was validated using a modified dynamic phantom with several breathing patterns. We compared the absorbed dose distributions derived from uncorrected(D)/corrected(D) images with static ones(D) in terms of γ-passing rates, 210 Gy isodose volumes, dose-volume histograms and percentage differences of mean doses (i.e., ΔD¯ and ΔD¯, respectively). The tool was applied to twelve SIRT patients and the Bland-Altman analysis was performed on mean doses.

Results: In the phantom study, the agreement between D and D was higher (γ-passing rates generally > 90%) than D and D. The isodose volumes in D were closer than D to D, with differences up to 10% and 30% respectively. A reduction from a median ΔD¯ = -19.3% to ΔD¯ = -0.9%, from ΔD¯ = -42.8% to ΔD¯ = -7.0% and from ΔD¯ = 1586% to ΔD¯ = 47.2% was observed in liver-, tumor- and lungs-like structures. The Bland-Altman analysis on patients showed variations (±50 Gy) and (±4 Gy) between D¯ and D¯ of tumor and lungs, respectively.

Conclusion: The proposed tool allowed the correction of Tc-MAA SPECT/CT images, improving the accuracy of the absorbed dose distribution.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2022.04.017DOI Listing

Publication Analysis

Top Keywords

tc-maa spect/ct
12
absorbed dose
12
dose inaccuracies
8
spect/ct images
8
γ-passing rates
8
isodose volumes
8
bland-altman analysis
8
novel tool
4
tool motion-related
4
dose
4

Similar Publications

Background: In radioembolization therapy for hepatic malignancies, the accurate estimation of lung shunt fraction (LSF) is crucial to minimize the risk of radiation-induced pneumonitis and fibrosis due to hepatopulmonary shunting of yttrium-90 (90Y)-microspheres. This study aimed to compare the accuracy and precision of LSF estimation using technetium-99m macroaggregated albumin single photon emission computed tomography ([99mTc]Tc-MAA SPECT) LSF, [99mTc]Tc-MAA planar LSF, and 90Y PET LSF in patients undergoing 90Y-radioembolization.

Material And Methods: A retrospective study was conducted involving 15 patients diagnosed with hepatocellular carcinoma (HCC) or liver metastases and planned to undergo transarterial radioembolization with 90Y SirSpheres after multidisplinary team discussion.

View Article and Find Full Text PDF

Purpose: Personalized treatment schemes are being systematically applied to ensure best treatment outcome in oncologic patients. This is true also for personalized dosimetry in transarterial radioembolization (TARE) in hepatocellular carcinoma (HCC) patients. Precise and detailed volumetric and functional data derived from radiological and nuclear imaging methods are essential for personalized dosimetry.

View Article and Find Full Text PDF

Background: Prior studies have established that macroaggregated albumin (MAA)-SPECT/CT offers more robust lung shunt fraction (LSF) and lung mean absorbed dose (LMD) estimates in Y radioembolization in comparison to planar imaging. However, incomplete SPECT/CT coverage of the lungs is common due to clinical workflows, complicating its potential use for LSF and LMD calculations. In this work, lung truncation in MAA-SPECT/CT was addressed via correction strategies to improve Y treatment planning.

View Article and Find Full Text PDF

Background: Transarterial radio-embolization (TARE) became a routine procedure for non-resectable liver tumor mainly hepatocellular carcinoma (HCC). Personalized dosimetry to the index lesion increased tumor response rate. However, there is no requirement to measure the precise activity injected during TARE.

View Article and Find Full Text PDF

Background: Overall Survival (OS) and Progression-Free Survival (PFS) analyses are crucial metrics for evaluating the efficacy and impact of treatment. This study evaluated the role of clinical biomarkers and dosimetry parameters on survival outcomes of patients undergoing Y selective internal radiation therapy (SIRT).

Materials/methods: This preliminary and retrospective analysis included 17 patients with hepatocellular carcinoma (HCC) treated with Y SIRT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!